article thumbnail

Acorda Says Tribunal Ignored Patent Law In MS Drug Feud

IP Law 360

million it won in arbitration against Irish biopharmaceutical company Alkermes in a licensing fight over a multiple sclerosis drug, arguing that the tribunal disregarded clear patent law. Acorda Pharmaceuticals pressed the Federal Circuit to award it nearly $66 million more than the $16.5

article thumbnail

4 Key Takeaways - Updates in Standard Essential Patent Licensing and Litigation

JD Supra Law

Kilpatrick’s Alton Absher and Andie Anderson recently presented “Updates in Standard Essential Patent Licensing and Litigation” at the firm’s annual 2024 Advanced Patent Law Seminar.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

[Video] 4 Key Takeaways | Updates in Standard Essential Patent Licensing and Litigation

JD Supra Law

Kilpatrick’s Alton Absher and Andie Anderson recently presented “Updates in Standard Essential Patent Licensing and Litigation” at the firm’s annual 2024 Advanced Patent Law Seminar.

article thumbnail

Compulsory licensing for expensive medicines: KCE report

SpicyIP

The Belgian Health Care Knowledge Centre (KCE) recently released an interesting report titled ‘Compulsory licensing for expensive medicines’. Ordinarily, patentees voluntarily decide whether or not and on what conditions to grant licenses to third parties. Failing which, a compulsory license can be issued. Natco Pharma Ltd.

Licensing 119
article thumbnail

Patent Law Textbooks: A Micro-Symposium

Patently-O

This Friday, November 5, the Iowa Innovation, Business & Law Center will be hosting a first-of-its-kind event (to the best of my knowledge at least): a panel discussion by patent law casebook authors about what makes their textbooks tick. Thomas, Cases and Materials on Patent Law (West Academic 2019).

article thumbnail

Preliminary Injunction and Patent License Disputes

Patently-O

Holt was part of forming two additional companies, BJM and Matrix and Symbiont licensed the technology (including the patent) to those companies. The agreement included a number of provisions — primarily a license with royalties for feed sold using the process. Nor do Plaintiffs’ claims raise novel patent issues.

article thumbnail

Covenant to not sue “at any time” terminated with the license agreement

Patently-O

provides a lesson into the importance of carefully drafting—and understanding—the scope of licensing terms, especially covenants not to sue. Background In 2005, AlexSam licensed its prepaid card patents to MasterCard in exchange for ongoing royalties based on the number of “Licensed Transactions.”